TaiRx
台睿生物科技股份有限公司
TaiRx is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is CVM-1118 (Phase 2; recruiting, HCC - Hepatocellular Carcinoma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| CVM-1118 | — | Phase 2; recruiting | HCC - Hepatocellular Carcinoma | China | 2026-07-23 | Trial registry |
| TRX-920 | — | Phase 1; recruiting | Advanced Solid Tumor | Taiwan | 2026-04-13 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.